Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.9
3.5
Journals
Metabolites
Special Issues
Future Trends and Emerging Applications in Metabolomics
share announcement

Future Trends and Emerging Applications in Metabolomics

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Nutrition and Metabolism".

Deadline for manuscript submissions: closed (15 April 2025) | Viewed by 2451

Special Issue Editors

Dr. Lenard Farczadi

E-Mail Website
Guest Editor
Centre for Advanced Medical and Pharmaceutical Research, “George Emil Palade” University of Medicine, Pharmacy, Science and Technology of Târgu Mures, 38 Gheorghe Marinescu Street, 540142 Targu Mures, Romania
Interests: bioanalysis; metabolomics; LC-MS; pharmaceuticals; nutritional supplements; fitopharmacy; pharmacokinetics; pharmacodynamics; pesticides
Dr. Ionela Hotea

E-Mail Website
Guest Editor
Faculty of Veterinary Medicine, University of Life Sciences “King Mihai I” from Timisoara, Calea Aradului, No. 119, 300645 Timisoara, Romania
Interests: animal nutrition; nutrients; metabolism; nutritional supplements; biomolecules; enzymes; nutrient absorption
Prof. Dr. Chengguo Xing

E-Mail Website
Guest Editor
Department of Medicinal Chemistry, University of Florida, Gainesville, FL 32610, USA
Interests: carcinogen metabolism and carcinogenesis; metabolite-based biomarkers; mass spectrometry; bioanalytical chemistry

Special Issue Information

Dear Colleagues,

We propose a Special Issue for the Journal Metabolites regarding metabolomics studies, including current and future trends, situated within the following current fields of studies: biological metabolites used as biomarkers for disease diagnostics; drug metabolism studies with a focus on metabolite interactions; novel bioanalytical approaches in the bioanalysis of biological and drug metabolism; advances in vivo study design (animal and human model) in metabolomics; study of nutraceuticals and nutrient metabolism; catabolism studies.

Liquid chromatography coupled with mass spectrometry, as one of the most powerful and widely used methods in the field of metabolomics studies, as well as the main field of study of one of the guest authors, will be the main focus of this Special Issue, but other types of bioanalytical methods are also of interest. Although the main focus in the field of metabolomics is on in vivo studies, interesting in-vitro studies with ramifications in the study of metabolic pathways could also be welcomed.

Dr. Lenard Farczadi
Dr. Ionela Hotea
Prof. Dr. Chengguo Xing
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • metabolomics
  • metabolism
  • interaction studies
  • pharmacokinetics
  • bioavailability
  • mass spectrometry
  • bioanalysis
  • biomarkers
  • nutrients
  • animal studies enzymes

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

16 pages, 1684 KiB  
Article
Development and Validation of a New LC-MS/MS Method for the Assay of Plasmatic Peripheral Short- and Medium-Chain Fatty Acids for Metabolomics Applications
by Lenard Farczadi, Laura Barcutean, Smaranda Maier, Rodica Balasa and Silvia Imre
Metabolites 2025, 15(6), 403; https://doi.org/10.3390/metabo15060403 - 16 Jun 2025
Abstract
Background: Short-chain fatty acids (SCFAs) and medium-chain fatty acids (MCFAs) are human metabolites which are involved in various biochemical processes and can offer valuable insights and information on various pathological and metabolic issues of patients. Accurate, precise, high-performance bioanalytical methods are important tools [...] Read more.
Background: Short-chain fatty acids (SCFAs) and medium-chain fatty acids (MCFAs) are human metabolites which are involved in various biochemical processes and can offer valuable insights and information on various pathological and metabolic issues of patients. Accurate, precise, high-performance bioanalytical methods are important tools in both research and diagnostics of many pathologies, with LC-MS being the most frequently used methodology in modern metabolomics studies. Methods: The current paper describes a complete LC-MS/MS methodology for the accurate quantification of total plasmatic SCFA concentrations in humans using high-resolution QTOF mass spectrometric detection, including sample cleanup, preparation, and derivatization. Results and Conclusions: The method was validated with regard to all relevant parameters (selectivity, sensitivity, accuracy, precision, linearity, recovery, carryover, and reproducibility of sample preparation) according to the current applicable guidelines and tested in an in vivo study to quantify peripheral SCFAs in human patients as biomarkers for gut–brain axis disruption. Full article
(This article belongs to the Special Issue Future Trends and Emerging Applications in Metabolomics)
►▼ Show Figures

Figure 1

12 pages, 987 KiB  
Article
Bupropion Increased More than Five Times the Systemic Exposure to Aripiprazole: An In Vivo Study in Wistar albino Rats
by Iulia-Maria Ciocotișan, Dana Maria Muntean and Laurian Vlase
Metabolites 2024, 14(11), 588; https://doi.org/10.3390/metabo14110588 - 30 Oct 2024
Cited by 1 | Viewed by 1921
Abstract
Background/Objectives: In psychiatric disorders, antipsychotics and antidepressant medication are often administered together. Aripiprazole, a third-generation antipsychotic drug, is extensively metabolized by CYP2D6 and CYP3A4 isoenzymes, while bupropion, used in depressive disorders, is known as a moderate or strong CYP2D6 enzyme inhibitor. This [...] Read more.
Background/Objectives: In psychiatric disorders, antipsychotics and antidepressant medication are often administered together. Aripiprazole, a third-generation antipsychotic drug, is extensively metabolized by CYP2D6 and CYP3A4 isoenzymes, while bupropion, used in depressive disorders, is known as a moderate or strong CYP2D6 enzyme inhibitor. This in vivo experiment aimed to assess the presence of a pharmacokinetic drug interaction between aripiprazole and bupropion and its magnitude on the systemic exposure of aripiprazole. Methods: 24 healthy Wistar albino male rats were included in two study groups. A single dose of 8 mg/kg aripiprazole was given to rats in the reference group, while the test group received repeated doses of bupropion for 6 days, followed by a single dose of aripiprazole. An LC-MS/MS method was developed for the concomitant quantification of aripiprazole and its active metabolite, dehydroaripiprazole, and non-compartmental analysis was employed to assess their pharmacokinetic parameters. Results: The mean AUC0-∞ of aripiprazole increased 5.65-fold (1117.34 ± 931.41 vs. 6311.66 ± 2978.71 hr·ng/mL), the mean Cmax increased by 96.76% and the apparent systemic clearance decreased over 9-fold after bupropion repeated doses. The exposure to aripiprazole’s active metabolite increased as well, having a 4-fold increase in the mean AUC0–∞ (from 461.13 ± 339.82 to 1878.66 ± 1446.91 hr·ng/mL) and a 2-fold increase in the mean Cmax. Conclusions: The total exposure to the aripiprazole parent compound and active moiety significantly increased after bupropion pretreatment in this preclinical in vivo experiment. Clinical studies should further establish the significance of this interaction in humans. Full article
(This article belongs to the Special Issue Future Trends and Emerging Applications in Metabolomics)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop